133 related articles for article (PubMed ID: 8774638)
21. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation.
Jacobs IJ; Kohler MF; Wiseman RW; Marks JR; Whitaker R; Kerns BA; Humphrey P; Berchuck A; Ponder BA; Bast RC
J Natl Cancer Inst; 1992 Dec; 84(23):1793-8. PubMed ID: 1433368
[TBL] [Abstract][Full Text] [Related]
22. Sam68 is Overexpressed in Epithelial Ovarian Cancer and Promotes Tumor Cell Proliferation.
Dong L; Che H; Li M; Li X
Med Sci Monit; 2016 Sep; 22():3248-56. PubMed ID: 27623016
[TBL] [Abstract][Full Text] [Related]
23. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies.
Salazar H; Godwin AK; Daly MB; Laub PB; Hogan WM; Rosenblum N; Boente MP; Lynch HT; Hamilton TC
J Natl Cancer Inst; 1996 Dec; 88(24):1810-20. PubMed ID: 8961970
[TBL] [Abstract][Full Text] [Related]
24. Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
Guo H; Xu Y; Wang F; Shen Z; Tuo X; Qian H; Wang H; Wang K
Oncol Rep; 2018 Dec; 40(6):3725-3733. PubMed ID: 30272366
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer.
Paudel D; Zhou W; Ouyang Y; Dong S; Huang Q; Giri R; Wang J; Tong X
Gene; 2016 Jul; 586(1):48-55. PubMed ID: 27048832
[TBL] [Abstract][Full Text] [Related]
26. Borderline Ovarian Tumors: Fifteen Years' Experience at a Scottish Tertiary Cancer Center.
May J; Skorupskaite K; Congiu M; Ghaoui N; Walker GA; Fegan S; Martin CW; O'Donnell RL
Int J Gynecol Cancer; 2018 Nov; 28(9):1683-1691. PubMed ID: 30365457
[TBL] [Abstract][Full Text] [Related]
27. Large-scale profiling of metabolic dysregulation in ovarian cancer.
Ke C; Hou Y; Zhang H; Fan L; Ge T; Guo B; Zhang F; Yang K; Wang J; Lou G; Li K
Int J Cancer; 2015 Feb; 136(3):516-26. PubMed ID: 24895217
[TBL] [Abstract][Full Text] [Related]
28. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
[TBL] [Abstract][Full Text] [Related]
29. Plasma fibrinogen levels in patients with benign and malignant ovarian tumors.
Hefler-Frischmuth K; Lafleur J; Hefler L; Polterauer S; Seebacher V; Reinthaller A; Grimm C
Gynecol Oncol; 2015 Mar; 136(3):567-70. PubMed ID: 25576886
[TBL] [Abstract][Full Text] [Related]
30. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival.
Mascarenhas C; Lambe M; Bellocco R; Bergfeldt K; Riman T; Persson I; Weiderpass E
Int J Cancer; 2006 Dec; 119(12):2907-15. PubMed ID: 16998830
[TBL] [Abstract][Full Text] [Related]
31. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
[TBL] [Abstract][Full Text] [Related]
32. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
33. Loss of heterozygosity and genomic instability in synchronous endometrioid tumors of the ovary and endometrium.
Shenson DL; Gallion HH; Powell DE; Pieretti M
Cancer; 1995 Aug; 76(4):650-7. PubMed ID: 8625160
[TBL] [Abstract][Full Text] [Related]
34. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.
Dion F; Mes-Masson AM; Seymour RJ; Provencher D; Tonin PN
Oncogene; 2000 Mar; 19(11):1466-72. PubMed ID: 10723138
[TBL] [Abstract][Full Text] [Related]
35. Histopathology and molecular biology of ovarian epithelial tumors.
Chuaqui RF; Cole KA; Emmert-Buck MR; Merino MJ
Ann Diagn Pathol; 1998 Jun; 2(3):195-207. PubMed ID: 9845739
[TBL] [Abstract][Full Text] [Related]
36. p63 expression in epithelial ovarian tumors.
Poli Neto OB; Candido Dos Reis FJ; Zambelli Ramalho LN; Nogueira AA; de Andrade JM
Int J Gynecol Cancer; 2006; 16(1):152-5. PubMed ID: 16445626
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal origin of peritoneal implants and lymph node deposits in serous borderline ovarian tumors (s-BOT) with high intratumoral homogeneity.
Horn LC; Höhn AK; Einenkel J; Siebolts U
Int J Gynecol Pathol; 2014 Nov; 33(6):592-7. PubMed ID: 25272298
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer.
Xu Y; Wang C; Zhang Y; Jia L; Huang J
Sci Rep; 2015 Jul; 5():12104. PubMed ID: 26175056
[TBL] [Abstract][Full Text] [Related]
39. TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.
El-Balat A; Schmeil I; Karn T; Becker S; Sänger N; Holtrich U; Arsenic R
Pathol Oncol Res; 2018 Apr; 24(2):277-282. PubMed ID: 28470574
[TBL] [Abstract][Full Text] [Related]
40. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
